Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
1996
11.3K+
LTM Revenue $1.7B
LTM EBITDA n/a
$581M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nu Skin has a last 12-month revenue of $1.7B and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Nu Skin achieved revenue of $1.7B and an EBITDA of -$78.8M.
Nu Skin expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Nu Skin valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $2.0B | $1.7B | XXX | XXX | XXX |
Gross Profit | $1.6B | $1.4B | XXX | XXX | XXX |
Gross Margin | 81% | 78% | XXX | XXX | XXX |
EBITDA | $139M | -$78.8M | XXX | XXX | XXX |
EBITDA Margin | 7% | -5% | XXX | XXX | XXX |
Net Profit | $105M | $8.6M | XXX | XXX | XXX |
Net Margin | 5% | 0% | XXX | XXX | XXX |
Net Debt | $138M | $247M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Nu Skin's stock price is $6.
Nu Skin has current market cap of $301M, and EV of $581M.
See Nu Skin trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$581M | $301M | XXX | XXX | XXX | XXX | $0.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Nu Skin has market cap of $301M and EV of $581M.
Nu Skin's trades at 0.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Nu Skin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nu Skin and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $581M | XXX | XXX | XXX |
EV/Revenue | 0.3x | XXX | XXX | XXX |
EV/EBITDA | -7.4x | XXX | XXX | XXX |
P/E | -2.1x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 8.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNu Skin's NTM/LTM revenue growth is -100%
Nu Skin's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Nu Skin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nu Skin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nu Skin and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -12% | XXX | XXX | XXX | XXX |
EBITDA Margin | -5% | XXX | XXX | XXX | XXX |
EBITDA Growth | -157% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 38% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 65% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nu Skin acquired XXX companies to date.
Last acquisition by Nu Skin was XXXXXXXX, XXXXX XXXXX XXXXXX . Nu Skin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Nu Skin founded? | Nu Skin was founded in 1996. |
Where is Nu Skin headquartered? | Nu Skin is headquartered in United States of America. |
How many employees does Nu Skin have? | As of today, Nu Skin has 11.3K+ employees. |
Who is the CEO of Nu Skin? | Nu Skin's CEO is Mr. Ryan S. Napierski. |
Is Nu Skin publicy listed? | Yes, Nu Skin is a public company listed on NYS. |
What is the stock symbol of Nu Skin? | Nu Skin trades under NUS ticker. |
When did Nu Skin go public? | Nu Skin went public in 1996. |
Who are competitors of Nu Skin? | Similar companies to Nu Skin include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
What is the current market cap of Nu Skin? | Nu Skin's current market cap is $301M |
What is the current revenue of Nu Skin? | Nu Skin's last 12-month revenue is $1.7B. |
What is the current EV/Revenue multiple of Nu Skin? | Current revenue multiple of Nu Skin is 0.3x. |
What is the current revenue growth of Nu Skin? | Nu Skin revenue growth between 2023 and 2024 was -12%. |
Is Nu Skin profitable? | Yes, Nu Skin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.